Allogeneic stem cell transplantation (allo-SCT), including HLAidentical sibling donor and alternative donor transplant, provides a potentially curable method for patients with hematological malignancies. 1 Rapid hematopoietic reconstitution and immune recovery are key steps to a successful transplantation. In allo-SCT settings, several studies have demonstrated the effects of cell compositions in allografts with clinical outcomes. [2] [3] [4] [5] [6] Previous studies show that donor characteristics, such as age, gender and body mass index, and donors' leukocyte count, contribute to the hematopoietic and immune cell yield, although controversy remains. [7] [8] [9] [10] However, nearly all of these studies focus on the correlation of adult demographic features with cell compositions in the allografts. Few studies have reported the impacts of pediatric donor characteristics on cell compositions in mixture allografts. 4 We prospectively analyzed 104 healthy pediatric donors who underwent granulocyte-CSF (G-CSF)-mobilized bone marrow (G-BM) and PBSC harvests (G-PB) between January 2014 and June 2016 to investigate the correlation between donor characteristics and the doses of hematopoietic and immune compositions in mixture allografts of G-PB and G-BM. The mobilization, bone marrow and peripheral blood allograft collection, flow cytometry evaluation of graft composition and statistical analysis were conducted according to our previous study. 9, 10 The characteristics and blood cell counts of 104 healthy donors are showed in 
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− T cells, were 60%, 60% and 65%, respectively.
In the current study, we demonstrated that donor age and the monocyte count pre-G-BM harvest were two variables that influence CD34
+ cell dose in the mixture allografts in the pediatric donor subpopulation. Other important findings are listed as follows: (1) 
− T cells; and (4) the CD14 + monocyte count pre-G-BM harvest might also predict the doses of the yields of CD14 + monocytes collected in mixture allografts. Our findings provide new data and indicate that donor characteristics may have effects on hematopoietic and immunological cell compositions not only in the adult population but also in the pediatric subpopulation.
Our previous study reported an association of high-dose CD34 + cell dose in allografts with rapid platelet engraftment. 3 In this study, negative effects of pediatric donor age with stem cell harvest were observed in mixture allografts, which is consistent with most previous studies. [7] [8] [9] Moresi et al. 11 reported that the absolute circulating CD34 + cell counts gradually and significantly decreased with advancing age, which may partly explain the finding that the younger the donor, the higher the dose of CD34 + cells. We also confirmed an association of monocytes pre-G-BM harvest, lymphocyte count before G-CSF administration and donor BMI with the yield of CD34 + cells (Table 2 ). Both effective and regulatory immune cells have effects on clinical outcomes after allo-SCT. 2 The association of a higher dose of CD8 + cytotoxic T cells (450th percentile) in allografts with rapid neutrophil reconstitution, enhanced immune recovery and decreased transplant-related mortality (TRM) has been reported in HLA-matched allo-SCT settings, leading to superior survival. 5 In a haploidentical modality, Dong et al. 6 showed that patients receiving high numbers of CD3 + cells (4177 × 10 6 /kg) in allografts experienced statistically less TRM and a significantly better overall survival. In this study, we observed that allografts collected from pediatric donors with high lymphocyte counts pre-G-BM harvest or with lower BMI, contained higher doses of CD3 + T cells, CD3 Tregs were confirmed as potential regulatory cells to mitigate GvHD and to promote nonmyeloablative bone marrow chimerism. 13 We found that CD3 + CD4 − CD8 − Tregs were expanded successfully at 60 days following transplantation, which could help avoid severe acute GvHD after haploidentical allografts.
14 Therefore, a higher dose of CD3 + CD4 − CD8 − T cells in allografts of pediatric donors with high lymphocyte counts pre-G-BM harvest, or with lower BMIs, might contribute to the lower incidence of GvHD, as previously reported by us. 14 We also showed that high monocyte counts pre-G-BM harvest was positively associated with high doses of CD14 + monocytes in allografts collected from pediatric donors. Previously, the immune regulatory roles of monocytes in G-CSF-mobilized harvests and their protective effects against GvHD were observed ex vivo and in vivo. 15 In addition, we showed an association of a higher dose of CD14 + monocyte with a higher possibility of platelet engraftment in aplastic anemia patients who received haploidentical allografts (unpublished data). Thus, choosing suitable pediatric donors with specific characteristics who may donate high doses of CD3 + CD4 −
− T cells and monocytes for infusion into recipients may contribute to alleviate GvHD after allo-SCT. [13] [14] [15] In agreement with our previous study, we also demonstrated a positive correlation between the monocyte count pre-harvest and the yield of CD14 + monocyte in allografts in the pediatric donor population. 10 However, in contrast to the data obtained from the general donor population, 9 we found that the lymphocyte count pre-harvest was positively associated not only with higher doses of CD3 + T cells and CD3 + CD8 + T cells but also with CD3 + CD4 + T cells and CD3 + CD4 − CD8 − T cells in mixture allografts. Therefore, our study provides further evidence suggesting that circulating monocyte and lymphocyte counts after treating donors in vivo are helpful parameters to predict the yields of hematopoietic and immunological subsets in allografts, respectively.
The limitations of this study are listed as follows. First, this was a single-center study; a multicenter study is warranted. Second, these results were obtained from a Chinese population; the possibility of extending these findings to other populations, 8 such as white, black and Hispanic populations, remains to be investigated. Third, circulating CD34 + cells were not routinely detected in our center.
In summary, the factors observed in the current study provide valuable information for optimal allograft harvests in the pediatric donor population. These data, together with findings from others 7, 8 and us, 9, 10 suggest that donor age, donor BMI, along with lymphocyte and monocyte counts before harvest are important variables influencing both hematopoietic and immunological cell subsets in allografts and may represent possible criteria to select a better donor. The application of our findings in allo-SCT settings, including haploidentical allografts, could result in optimal hematopoietic and immune cell yields by harvest and improved clinical outcomes.
